SARS-CoV-2 Viral Variants—Tackling a Moving Target | Vaccination | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

SARS-CoV-2 Viral Variants—Tackling a Moving Target

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME

In this issue of JAMA, Zhang and colleagues1 report the emergence of a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant in Southern California that accounted for 44% (37 of 85) of samples collected and studied in January 2021. The terminology of viral variation can be confusing because the media and even scientific communications often use the terms variant, strain, and lineage interchangeably. The terminology reflects the basic replication biology of RNA viruses that results in the introduction of mutations throughout the viral genome. When specific mutations, or sets of mutations, are selected through numerous rounds of viral replication, a new variant can emerge. If the sequence variation produces a virus with distinctly different phenotypic characteristics, the variant is co-termed a strain. When through genetic sequencing and phylogenetic analysis a new variant is detected as a distinct branch on a phylogenetic tree, a new lineage is born.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Corresponding Author: John R. Mascola, MD, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Dr, Bethesda, MD 20853 (jmascola@mail.nih.gov).

Published Online: February 11, 2021. doi:10.1001/jama.2021.2088

Conflict of Interest Disclosures: Dr Graham reports a patent for design of spike antigens with stabilizing mutations with multiple nonexclusive licenses for use in candidate vaccines. No other disclosures were reported.

References
1.
Zhang  W , Davis  BD , Chen  SS ,  et al.  Emergence of a novel SARS-CoV-2 strain in Southern California.   JAMA. Published online February 11, 2021. doi:10.1001/jama.2021.1612Google Scholar
2.
Nextstrain. Accessed February 8, 2021. https://nextstrain.org/
3.
PANGO lineages. Accessed February 8, 2021. https://cov-lineages.org
4.
Korber  B , Fischer  WM , Gnanakaran  S ,  et al; Sheffield COVID-19 Genomics Group.  Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus.   Cell. 2020;182(4):812-827.e19. doi:10.1016/j.cell.2020.06.043PubMedGoogle ScholarCrossref
5.
Yurkovetskiy  L , Wang  X , Pascal  KE ,  et al.  Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant.   Cell. 2020;183(3):739-751.e8. doi:10.1016/j.cell.2020.09.032PubMedGoogle ScholarCrossref
6.
Hou  YJ , Chiba  S , Halfmann  P ,  et al.  SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo.   Science. 2020;370(6523):1464-1468. doi:10.1126/science.abe8499PubMedGoogle Scholar
7.
Rambaut  A , Loman  N , Pybus  O ,  et al; COVID-19 Genomics Consortium UK. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. Virological.org. Posted December 18, 2020. Accessed January 3, 2021. https://virological.org/t/preliminary-genomic-characterisation-of-anemergent-sars-cov-2-lineage-in-the-uk-definedby-a-novel-set-of-spike-mutations/563
8.
Horby P, Huntley C, Davies N, et al. Paper from the New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) on new coronavirus (COVID-19) variant B.1.1.7. Posted January 21, 2021. Accessed February 8, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/955239/NERVTAG_paper_on_variant_of_concern__VOC__B.1.1.7.pdf
9.
Tegally  H , Wilkinson  E , Giovanetti  M ,  et al.  Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa.   medRxiv. Preprint published online December 22, 2020. doi:10.1101/2020.12.21.20248640Google Scholar
10.
Wibmer  CK , Ayres  F , Hermanus  T ,  et al.  SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.   bioRxiv. Preprint published online January 19, 2021. doi:10.1101/2021.01.18.427166Google Scholar
11.
Wu  K , Werner  AP , Moliva  JI ,  et al.  mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants.   bioRxiv. Preprint published online January 25, 2021. doi:10.1101/2021.01.25.427948Google Scholar
12.
Ho  D , Wang  P , Liu  L ,  et al.  Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization.   Res Sq. Preprint published online January 29, 2021. doi:10.21203/rs.3.rs-155394/v1Google Scholar
13.
Johnson & Johnson announces single-shot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of its phase 3 ENSEMBLE trial. Johnson & Johnson. Posted January 29, 2021. Accessed February 8, 2021. https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial
14.
Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial. Novavax. Posted January 28, 2021. Accessed February 8, 2021. https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close